Advyzon Investment Management LLC Makes New $392,000 Investment in Pfizer Inc. (NYSE:PFE)

Advyzon Investment Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,772 shares of the biopharmaceutical company's stock, valued at approximately $392,000.

Other institutional investors also recently modified their holdings of the company. Swedbank AB raised its position in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock valued at $166,284,000 after purchasing an additional 37,636 shares during the last quarter. Copeland Capital Management LLC bought a new position in Pfizer in the 3rd quarter valued at approximately $144,000. Sequoia Financial Advisors LLC grew its holdings in Pfizer by 55.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 422,143 shares of the biopharmaceutical company's stock worth $12,217,000 after acquiring an additional 151,293 shares during the last quarter. Eastern Bank increased its position in Pfizer by 481.4% in the 3rd quarter. Eastern Bank now owns 107,466 shares of the biopharmaceutical company's stock valued at $3,110,000 after acquiring an additional 88,982 shares during the period. Finally, Symphony Financial Ltd. Co. raised its stake in shares of Pfizer by 19.1% during the third quarter. Symphony Financial Ltd. Co. now owns 41,106 shares of the biopharmaceutical company's stock valued at $1,181,000 after acquiring an additional 6,586 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on PFE. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Up 1.6 %

NYSE PFE traded up $0.42 during trading hours on Friday, reaching $26.32. 45,181,154 shares of the company's stock traded hands, compared to its average volume of 38,114,637. The firm has a 50-day simple moving average of $26.28 and a 200 day simple moving average of $27.44. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market cap of $149.14 billion, a PE ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.